Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 17HMG (Human Menopausal Gonadotropin) literatureeuropepmc · Case report2026

Simultaneous trophectoderm biopsies enable preimplantation genetic testing for monogenic disorders in de novo case of incontinentia pigmenti: case report.

Simultaneous trophectoderm biopsies may enable preimplantation genetic testing in challenging cases of de novo incontinentia pigmenti, but further research is needed to confirm these findings.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the hmg (human menopausal gonadotropin) corpus
0
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This case report describes the use of two simultaneous trophectoderm biopsies for preimplantation genetic testing for monogenic disorders in a 29-year-old woman with de novo incontinentia pigmenti. The procedure resulted in the successful development of a PGT-M test and the generation of 10 euploid embryos that tested negative for the IKBKG deletion. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
10 euploid embryos tested negative for the IKBKG deletion.2026

Abstract

The authors’ words, as europepmc supplied them

<h4>Objective</h4>To describe the use of two simultaneous trophectoderm biopsies as a method to establish linkage analysis for preimplantation genetic testing for monogenic disorders (PGT-M) test development in a case of de novo incontinentia pigmenti (IP).<h4>Design</h4>Case report.<h4>Subject</h4>A 29-year-old nulligravid woman with de novo IP, confirmed to have the common, large deletion of exons 4-10 in the <i>IKBKG</i> gene. Negative maternal testing confirmed the mutation was de novo in our patient.<h4>Exposure</h4>Two simultaneous trophectoderm biopsies from a minimum of four embryos were obtained to enable two independent deoxyribonucleic acid preparations. This approach was utilized to complete linkage analysis, facilitating successful test development for PGT-M.<h4>Main outcome measures</h4>PGT-M test development and subsequent intracytoplasmic sperm injection/PGT-M cycle targeting the <i>IKBKG</i> deletion.<h4>Results</h4>PGT-M test development was successful. The patient underwent two antagonist stimulation protocols with intracytoplasmic sperm injection and PGT-M, yielding 10 euploid embryos that tested negative for the <i>IKBKG</i> deletion and were deemed suitable for transfer.<h4>Conclusions</h4>PGT-M for de novo IP is particularly challenging given the presence of the <i>IKBKGP1</i> pseudogene, its terminal location, and the fact that indirect linkage analysis is necessary for large gene deletions. Without genetic information from parents and offspring, PGT-M test development is frequently unsuccessful. This case demonstrates that simultaneous trophectoderm biopsies can enable PGT-M in otherwise ineligible cases, offering a viable path forward for patients affected by de novo IP.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the HMG (Human Menopausal Gonadotropin) corpus

BComparison between the efficacy of short and long GnRH-a protocols as a clinical outcome for viable pregnancies in women undergoing IVF/ICSI Cycles.biorxiv-preprint · 2021 · Clinical pregnancy rates: LAP 33.12% vs SAP 28.23%, p=0.001.HumanBRecombinant Follicular Stimulating Hormone Plus Recombinant Luteinizing Hormone Versus Human Menopausal Gonadotropins- Does the Source of LH Bioactivity Affect Ovarian Stimulation Outcome?biorxiv-preprint · 2021 · Mean number of mature oocytes retrieved: 10 ± 5.8 in rFSH+rLH vs 8.3 ± 4.6 in HP-hMG, p=0.01.HumanBUsing Letrozole Cotreatment With Progestin-Primed Ovarian Stimulation In Women With Polycystic Ovary Syndrome Treated For IVFbiorxiv-preprint · 2021 · 42.22% implantation rate in letrozole group vs. 34.69% in control group, p<0.05HumanBEvaluation of assisted reproductive technology treatment outcomes based on stimulation dosages and anti-Mullerian hormone levelsbiorxiv-preprint · 2022 · Not reported in abstract.HumanBHighly purified-hMG versus rFSH in ovarian hyperstimulation in women undergoing elective fertility preservationbiorxiv-preprint · 2023 · Peak estradiol level was significantly lower in the rFSH group (2547.18±1648.21 pg/mL) than in the hp-hMG group (3468.02±2497.69 pg/mL, P<0.001).HumanBA FSH-secreting pituitary adenoma discovered after ovarian hyperstimulation syndrome: a case report, illustrating pitfalls in the interpretation of serum FSH levelsbiorxiv-preprint · 2024 · Estradiol elevated at 737 pg/ml.Human